托鲁地文拉法辛在大鼠和人体中与多巴胺转运体(DAT)结合的PET/CT研究
本研究用PET/CT评估三重再摄取抑制剂托鲁地文拉法辛与DAT的结合能力,大鼠用[18F]FECNT、人体用[11C]CFT作为示踪剂,并用微透析测大鼠纹状体多巴胺水平。大鼠静脉9 mg/kg后微泵输注3 mg/kg,扫描45分钟内纹状体DAT结合率为3.7%–32.41%、下丘脑为5.91%–17.52%;口服32 mg/kg使纹状体多巴胺AUC0–180分钟增加63.9%。健康志愿者每日160 mg缓释片4天后,基底节DAT平均占据率给药后6小时为8.04%±7.75%、10小时为8.09%±7.00%。
要点
- 大鼠静脉9 mg/kg后微泵输注3 mg/kg,45分钟扫描期纹状体DAT结合率3.7%–32.41%、下丘脑5.91%–17.52%。
- 大鼠口服32 mg/kg托鲁地文拉法辛盐酸盐使纹状体多巴胺AUC0–180分钟增加63.9%。
- 健康志愿者每日160 mg缓释片4天后基底节DAT平均占据率6小时8.04%±7.75%、10小时8.09%±7.00%。
核心结论
- 结果首次在大鼠和人体中用PET/CT确认托鲁地文拉法辛与DAT结合并升高脑内多巴胺水平,可能有助于理解三重再摄取抑制剂的独特药理与功能效应。
研究设计与样本
- 在健康大鼠和人类受试者中用PET/CT检查DAT结合能力,大鼠另用微透析检查纹状体多巴胺水平。
- 大鼠研究用[18F]FECNT、人体研究用[11C]CFT作为PET/CT放射性示踪剂。
主要发现
- 大鼠静脉给予托鲁地文拉法辛盐酸盐9 mg/kg后经微泵输注3 mg/kg,45分钟扫描期内纹状体DAT结合率为3.7%–32.41%、下丘脑DAT结合率为5.91%–17.52%。
- 大鼠口服托鲁地文拉法辛盐酸盐32 mg/kg显著升高纹状体多巴胺水平,AUC0–180分钟增加63.9%。
- 健康志愿者每日服用托鲁地文拉法辛盐酸盐缓释片160 mg共4天,给药后6小时和10小时基底节DAT平均占据率分别为8.04%±7.75%和8.09%±7.00%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Toludesvenlafaxine is a recently developed antidepressant that belongs to the triple reuptake inhibitor class. Despite the in vitro evidence that toludesvenlafaxine inhibits the reuptake of serotonin (5-HT), norepinephrine (NE) and dopamine (DA), there is no in vivo evidence that toludesvenlafaxine binds to DAT and increases DA level, a mechanism thought to contribute to its favorable clinical performance. METHODS: Positron emission tomography/computed tomography (PET/CT) was used to examine the DAT binding capacity in healthy rats and human subjects and microdialysis was used to examine the striatal DA level in rats. [18F]FECNT and [11C]CFT were used as PET/CT radioactive tracer for rat and human studies, respectively. RESULTS: In rats, 9 mg/kg of toludesvenlafaxine hydrochloride (i.v.) followed by an infusion of 3 mg/kg via minipump led to the binding rate to striatum DAT at 3.7 - 32.41% and to hypothalamus DAT at 5.91 - 17.52% during the 45 min scanning period. 32 mg/kg oral administration with toludesvenlafaxine hydrochloride significantly increased the striatal DA level with the AUC0 - 180 min increased by 63.9%. In healthy volunteers, 160 mg daily toludesvenlafaxine hydrochloride sustained-release tablets for 4 days led to an average occupancy rates of DAT at 8.04% ± 7.75% and 8.09% ± 7.00%, respectively, in basal ganglion 6 h and 10 h postdose. CONCLUSION: These results represent the first to confirm the binding of toludesvenlafaxine to DAT in both rats and humans using PET/CT, and its elevation of brain DA level, which may help understand the unique pharmacological and functional effects of triple reuptake inhibitors such as toludesvenlafaxine. GOV IDENTIFIERS: NCT05905120. Registered 14 June 2023. (retrospectively registered).
引用
- Huang Z, Wu J, Guan Y, et al. PET/CT study of dopamine transporter (DAT) binding with the triple reuptake inhibitor toludesvenlafaxine in rats and humans. Eur J Nucl Med Mol Imaging. 2024. PMID: 38587645. doi:10.1007/s00259-024-06700-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。